References
  1. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science. 2020.
  2. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui D, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020. PMID: 32109013.
  3. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y, Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis, International Journal of Infectious Diseases
  4. Toshiyuki Matsumoto, Ryoji Ozono, Tetsuya Oshima, Hideo Matsuura, Taijiro Sueda, Goro Kajiyama, Masayuki Kambe, Type 2 angiotensin II receptor is downregulated in cardiomyocytes of patients with heart failure, Cardiovascular Research , Volume 46, Issue 1, April 2000, Pages 73–81,
  5. Juan Meng, Guohui Xiao, Juanjuan Zhang, Xing He, Min Ou, Jing Bi, Rongqing Yang, Wencheng Di, Zhaoqin Wang, Zigang Li, Hong Gao, Lei Liu & Guoliang Zhang (2020) Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension, Emerging Microbes & Infections, 9:1, 757-760, DOI: 10.1080/22221751.2020.1746200